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ABSTRACT
Objective: To investigate the variance in reported prevalence rates of permanent neonatal hearing
impairment (HI) worldwide.
Design: A systematic review and meta-analysis was performed on reported prevalence rates of sensori-
neural and permanent conductive or mixed HI worse than 40dB in neonates, detected as a result of a
screening programme or audiometric study.
Study sample: For meta-analysis, 35 articles were selected, 25 from high-income countries and 10 from
middle-income countries according to the world bank classification system.
Results: The prevalence rate of permanent uni- and bilateral HI worse than 40dB in neonates varied
from 1 to 6 per 1000, the overall prevalence was 2.21 per 1000 [1.71, 2.8]. In NICU populations the preva-
lence rate was higher with a larger fraction of bilateral cases. Although not significant, prevalence rates
were slightly higher in Asia compared to Europe and the number of infants lost to follow-up appeared
higher in countries with lower gross national income.
Conclusion: Substantial variations exist in prevalence rates of neonatal permanent HI across countries
and regions. There is a strong need for more data from low-income countries to identify demographic
factors that account for this variability in reported prevalence rates. Reporting these data in a uniform
way is advocated.
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Introduction
Hearing impairment (HI) is a rather common sensory deficit in
children in their first years of life, but it is not easily noticed.
Deficiency in auditory input at a young age may cause a delay in
speech, language and general development and poor academic
performance (Yoshinaga-Itano and Apuzzo 1998a, 1998b). Early
detection of congenital HI and appropriate intervention is crucial
to minimise its impact (Joint Committee on Infant Hearing,
American Academy of Pediatrics 2007; Downs and Yoshinaga-
Itano 1999).
Prevalence rates of HI at various ages and from all over the
world are indispensable to better understand the pathophysiology
of HI and to organise health care provisions such as detection,
intervention and prevention.
Permanent hearing impairment (PHI) in childhood is caused
by both genetic factors and environmental factors. These factors
are likely to vary across the world (Grundfast 2002; Smith and
Taggart 2004). Neonatal PHI of genetic origin is in many cases
autosomal recessive (Grundfast 2002; Smith and Taggart 2004;
Denoyelle et al. 1997; Zelante et al. 1997). PHI can also be
acquired in utero or during early childhood as a complication of
infectious disease, a consequence of ototoxic medication, or in
connection with premature birth. This explains the higher preva-
lence of PHI in infants treated at the neonatal intensive care unit
(NICU) (Grundfast 2002). Variations exist in the worldwide
availability and quality of health care provisions such as birth
clinics, NICU’s, medication and vaccination programmes. The
aforementioned factors all influence the prevalence of neonatal
PHI to some extent an may cause variations across the world.
The World Health Organization (WHO) (2018) reported that
prevalence rates of HI are higher in low-income countries
(Mathers, Smith, and Concha 2003; Stevens et al. 2013).
However, these concerns both conductive and sensorineural HI
in children at school age, when otitis media plays an important
role (Mathers, Smith, and Concha 2003; Stevens et al. 2013;
Smith 2008). The Global Research on Developmental Disabilities
Collaborators (2018) estimated the number of children with HI
to be the highest in South Asia and the lowest in North
America. The highest number of children with or at risk for
developmental disabilities were found in low- and middle-
income countries such as India, China and Nigeria.
During the past 20 years universal neonatal hearing screening
(NHS) programmes, targeted at detecting PHI, have been intro-
duced in many high- and middle-income countries (Joint
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2007). In some countries, NHS has been implemented at a local
level or for a limited period of time. As a result, prevalence rates
of PHI in neonates from a variety of countries are increasingly
becoming available. This new knowledge may help to find
explanations for variations in prevalence rates.
Most NHS programmes aim to detect PHI >40 dB HL, and
use a two- or three-step screening protocol (Sloot et al. 2015;
Vos et al. 2016; Kanji, Khoza-Shangase, and Moroe 2018). Two
types of objective screening tests are most commonly used: otoa-
coustic emission tests (OAE) and automated auditory brainstem
response tests (aABR). An OAE measures the reaction (emis-
sions) of the outer hair cells in the cochlea to an auditory stimu-
lus, presented in the infant’s ear canal. An aABR measures the
electrical response of the auditory brainstem to an auditory
stimulus set at 35 or 40 dB nHL. Both tests detect HI worse than
40 dB HL, and have high sensitivity and specificity (Wolff et al.
2010). In contrast to OAE, aABR screening is able to also detect
cases of auditory neuropathy. An infant who fails the first step
of the screening programme is invited to return for the next step
of screening. The specificity of a screening programme increases
with the number of steps used.
Infants are referred for full diagnostic assessment when they
have failed the final step of the screening programme. Auditory
brainstem response (ABR) and auditory steady-state responses
(ASSR), which measure the electrical response in the central
auditory pathway, are used to objectively estimate the hearing
threshold. Quite often more extensive examinations are needed
to obtain a final diagnostic result that includes type of HI and
the threshold.
The aim of this study is to investigate the prevalence of PHI
in neonates by means of a systematic literature review and ana-
lyse the results using a Bayesian meta-analysis. In more detail,
we aim to:
 Summarise the literature that reports on the prevalence of
neonatal PHI of 40 dB or worse;
 Combine the findings in a meta-analysis to obtain an accur-
ate estimation of the overall prevalence rate of neo-
natal PHI;
 Analyse the degree of variation in reported prevalence rates
of neonatal PHI and identify explanatory factors.
Materials and methods
Literature search
Current scientific literature was systematically searched to iden-
tify original peer-reviewed studies that explore the prevalence of
permanent sensorineural or conductive HI in children. This
review was carried out based on the guidelines of Preferred
Reporting Items for Systematic Review and Meta-Analysis
Protocols (PRISMA P) 2015 statement. This includes the use of
the PRISMA P checklist and following the methodological
approaches recommended for systematic reviews based on the
PRISMA statement (Moher et al. 2015; Shamseer et al. 2015).
The systematic literature search was carried out in November
2017, and updated in November 2018, within the following elec-
tronic databases: Embase, PubMed/Medline Ovid, Web of
Science, Cochrane Central and Google Scholar. Search terms
included: “prevalence”, “incidence”, “epidemiology”, “hearing dis-
order”, “hearing impairment”, “pediatric”, “preschool”,
“newborn”, “infant”, “child”, which were used to develop a
search string. These terms were combined in different ways using
Boolean operators such as “AND” and “OR”. The complete
search strings used have been attached in Appendix 1 (see
Supplementary material). Although the search included infants
up to 12 years of age, in this study we only consider articles that
describe the prevalence of infants up to one year of age.
The articles obtained from the electronic databases were com-
piled using EndNote and duplicates were eliminated. All titles
and abstracts were screened independently by three reviewers
(A.B., H.H., A.M.). Studies were included in the literature review
if they contained original data on prevalence rates of PHI
among the general infant population or subgroups: infants
admitted to the NICU and/or well babies (WB). Studies were
excluded if they reported only on subgroups of infants (e.g.
infants with syndromes), if the study population or threshold
were poorly defined, if the diagnostic process was not described,
if errors were made when calculating the prevalence rate, or if
the full text was not available in English. Definitions of the terms
used in this article are provided in Table 1.
The remaining articles underwent a full-text review by two
authors (A.B. and H.H.), and further selection was made based
on a number of inclusion and exclusion criteria. Studies were
included if they reported on sensorineural and permanent con-
ductive or mixed HI, considered both bilateral and unilateral
PHI or bilateral PHI only, and used hearing thresholds from 20
to 40 dB HL. PHI had to be diagnosed as a result of a screening
programme or audiometric study and confirmed by means of
ABR or ASSR. During the diagnostic process following a NHS
programme, a number of tests may be needed to determine the
definitive hearing thresholds. When studies reported on the vari-
ability of these results, the most definitive result obtained during
the first year of life was used to calculate the prevalence rate.
When more than one study reported on the same population,
prevalence rates were used from the most recent study that
adequately met all inclusion criteria.
Studies were excluded if they reported on transient HI only
or when transient HI figures were not eliminated from the final
reported prevalence rates. This selection also excluded all articles
that reported prevalence on older children, the selection focussed
only on the prevalence of PHI in infants. Disagreements about
Table 1. Definitions.
PHI Permanent hearing impairment includes sensorineural, permanent conductive (e.g. malformation), and excludes transient hearing
impairment (e.g. otitis media), in one or both ears.
Bilateral PHI Permanent hearing impairment of both ears. The degree of PHI is determined by the better hearing ear.
Unilateral PHI Permanent hearing impairment in one ear. The degree of PHI is determined by the worse hearing ear.
Population The number of neonates that entered the screening programme or study.
NICU/WB Within the neonatal population, two subgroups are defined: NICU indicates infants treated in a neonatal intensive care unit (NICU), and
well babies (WB) are all other infants.
General population The neonatal population that includes all subgroups.
Prevalence The number of neonates with PHI in the population.
Prevalence rate The number of neonates with PHI per 1000 of the population.
2 A. M. L. BUSSÉ ET AL.
the interpretation of data were resolved by discussion, and when
disagreements could not be resolved, A.G. acted as a referee.
Prevalence rates for a hearing threshold of 35 or 40 dB HL
were used when this information was available. Some studies
reported only on prevalence rates for thresholds of 20, 25 or
30 dB HL. All reported prevalence rates resulted from a study
using OAE, aABR or ABR.
Selected studies
A data extraction sheet was developed to record specific infor-
mation from the article (title, author, year), year(s) when the
data were collected, information about the population (geo-
graphic, ethnic, socio-economic), general neonatal population or
NICU/WB subgroups, population size, definition of PHI, screen-
ing and diagnostic tests, degree of PHI, unilateral or bilateral
PHI, age at time of diagnosis, percentage lost to follow-up
(LTFU), and prevalence rate of PHI.
The Newcastle Ottawa Scale (Wells et al. 2018) is a quality
assessment tool for cohort studies used to score the quality of
studies included in reviews. Since not all subscales of the
Newcastle Ottawa Scale were applicable to our set of data, we
adapted the criteria to fit our study. This resulted in a list of
seven items (Table 2). Criteria were scored on a two-point or
three-point scale. For study group composition, a representative
group was one in which no more than 10% of infants were
admitted to the NICU (Harrison and Goodman 2015; Gijsen and
Harbers 2015). The criterion “percentage of infants LTFU” was
based on the recommendations of the JCIH to achieve a return-
to-follow-up of 70% of infants or more (Joint Committee on
Infant Hearing, American Academy of Pediatrics 2007; Joint
Committee on Infant Hearing 2000; Prieve and Stevens 2000).
Inadequate accuracy concerned ambiguity such as calculation
uncertainties. The final quality score was calculated to a max-
imum of eight points and converted to a percentage. The cut-off
value was set at 75% to distinguish between studies of low and
high quality.
The countries of the study populations were classified into
five geographical areas: Europe, Asia, the Americas, Africa and
Australia. Websites of The World Bank Group (2018) and
National Statistics Republic of China (Taiwan) for Taiwan (2018)
were consulted to classify each country as high, upper-middle,
lower-middle or low-income country, and to record its Gross
National Income (GNI) per capita in 2017.
Statistical analysis
A Bayesian random-effects meta-analysis was used to estimate
the prevalence rate of both unilateral and bilateral HI in different
populations. Prevalence rates were estimated for the general neo-
natal population and separately for WB and infants admitted to
NICU for the studies in which these numbers were reported on.
The central idea of the Bayesian approach is to combine the
likelihood (data) with our prior knowledge to result in a revised
probability (posterior probability). Posterior distributions are
typically summarised by the median and the 95% credible inter-
vals, which are the counterparts to 95% confidence intervals used
in classical statistics.
The Bayesian approach is becoming more popular because it
is intuitive and flexible due to recent advances in computational
methods. In a meta-analysis framework, a Bayesian approach
offers an advantage compared to the classical approach, espe-
cially when taking into account the limitations in misestimating
the heterogeneity in a random-effects model (Sutton et al. 2000;
Sutton and Abrams 2001). Statistical expertise has strongly rec-
ommended carrying out Bayesian meta-analyses (Higgins and
Green 2011). In our model, random-effects were employed to
take into account the heterogeneity between the studies. The SD
of the random effects (tau) will be reported as the heterogen-
eity index.
In this study, we employed relatively non-informative
priors for all parameters. We performed different relatively non-
informative priors on random-effects’ variance (i.e. an inverted
gamma-distribution with low values and a uniform prior to the
random-effects SD) as a sensitivity analysis to check the robust-
ness of our meta-analysis results.
We performed two other sensitivity analyses. These aimed to
assess the impact of variations of information that were imple-
mented into the analytical model. One sensitivity analysis was
performed using only high-quality studies (defined as 75% on
the quality score), and the other one was performed using only
studies where NHS programmes targeted a strict threshold of
35 dB HL or worse.
A Bayesian random-effects meta-regression was performed to
assess the relationship between the overall prevalence rate of HI
and the GNI per capita, infants LTFU, and geographical area.
The calculated exceedance probability describes the posterior
probability that the estimated parameter is greater or smaller
than zero. The exceedance probability is a counterpart to the
p value that is used in classical statistics. Extreme values for the
exceedance probability (i.e. <0.05) indicate a significant
difference.
Computations and graphics were performed in R programme
language (Dalgaard 2010). All Bayesian computations were per-
formed using the Markov Chain Monte Carlo sampler through
Jags (Plummer 2016) interface in R programme language.
Markov Chain Monte Carlo sampling was run for each analysis
for 50k iterations after discarding the first 50k iterations (burn-
in) to reach the convergence. The 95% credible intervals use
95% of the highest posterior probability in the posterior
distribution.
The Egger test was used to check the publication bias via
the metafor package (Viechtbauer 2010) in R programme
language.
Table 2. List of criteria to indicate quality of the studies included for the meta-analysis.
Criterion 0 1 2
Study group composition Not representative/not mentioned Representative
Study group origin Hospital(s) Region/country
Study group size <5000 5000–10,000 >10,000
HI type(s) Not well defined Well defined
HI threshold <35 dB 35 or 40 dB
% lost to follow-up 30%/not mentioned <30%
Accuracy Inadequate Adequate
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Results
Our search strategy identified 7520 articles (Figure 1). After
duplicates were eliminated, 4497 articles remained. Titles and
abstracts were screened, and a further 4117 were eliminated
because the inclusion criteria were not met or full text was not
available in English. Of the remaining 380 articles on childhood
PHI, 243 focussed on infants in their first year of life. A total of
209 of these 243 articles were excluded because they did not
meet the inclusion criteria. Although some of these excluded
studies reported on the prevalence of neonatal PHI, they were
not used in our review for a variety of reasons: the composition
of the study group was not suitable, the screening procedure,
tests, or number of ears tested were not described, the descrip-
tion of results of post-screen diagnostics were insufficient or
absent, PHI was poorly or not defined, PHI thresholds were not
mentioned, the study design was unclear, or obvious calculation
errors were found. The update of this search in November 2018
identified 278 additional articles. One was included in the final
analysis of 35 articles (Table 3).
Most of the 35 studies included in the analysis were con-
ducted in Europe, Asia, North America and Australia in the past
20 years. Only a few were conducted in Africa and South
America. Twenty-five studies originate from high-income coun-
tries, eight from upper-middle-income countries and two from
lower-middle-income countries. Thirteen studies had a quality
score >75%. In particular, lower scores were achieved on the cri-
teria composition of study group, local or national study group,
and numbers LTFU (Figure 2).
Prevalence rates were often readily presented in the article or
were calculated from the supplied data. Only a few studies
provided multiple thresholds obtained throughout the diagnostic
process. Most studies reported prevalence rates with thresholds
of 35 or 40 dB HL. However, for some studies only thresholds of
20, 25 or 30 dB HL were available. Notwithstanding this incon-
sistency, all studies screened for a target condition of 35 or 40 dB
HL using OAE or aABR in a two-, three- or four-step screening
programme. These techniques identify HI of 35–40 dB HL or
worse, with a high specificity. How many cases of mild HI
(20–40 dB HL) would actually be included in the prevalence rate
estimations with a threshold of 20 dB HL depends on the specifi-
city of the applied screening programme. Therefore, the impact
of varying thresholds was evaluated in a sensitivity analysis.
Table 4 displays the prevalence rates of PHI (bilateral and
unilateral) and PHI bilateral only for the general population of
infants, the WB subgroup and the NICU infant subgroup as they
are reported in each article.
The Bayesian random-effects meta-analysis of the prevalence
rates of PHI in the general neonatal population resulted in an
overall prevalence rate of 2.21 per 1000 with a credible interval
of [1.71, 2.8] (Tau: 0.51 95% CI (0.34, 0.73)) (Table 5). The cor-
responding forest plot is depicted in Figure 3, in which studies
are ranked according to GNI per capita in the country of origin.
The highest prevalence rates were found in Nigeria (Olusanya
and Somefun 2009), India (Augustine et al. 2014), China (Hong-
Kong) (Ng et al. 2004) and Iran (Farhat et al. 2015). The lowest
prevalence rates were found in Ireland (Adelola et al. 2010),
South Africa (Swanepoel et al. 2007), Brazil (Bevilacqua et al.
2010) and China (Shanghai) (Sun et al. 2009). The prevalence
rate for bilateral PHI only (unilateral PHI excluded) was 1.33 per
1000 [1.01, 1.63], which is about 2/3 of the overall prevalence
Figure 1. Flowchart showing the process followed to identify, screen, determine eligibility and select articles for inclusion in this review. The number of articles for
each step is displayed as (the original searchþ the search update).
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rate. The prevalence rate for unilateral PHI only (bilateral PHI
excluded) was 0.78 per 1000 [0.51, 1.07] (Table 5).
Additional meta-analyses were performed for the studies
reporting on NICU and WB populations. Table 5 summarises
the most relevant results. The prevalence rate in the WB popula-
tion (1.93 [1.06, 2.98]) was lower than the prevalence rate for the
general neonatal population (2.21 [1.71, 2.8]). As expected, a
substantially higher prevalence rate was found for NICU infants
(15.77 [4.65, 29.25]) when compared to both the general and
WB population (Table 5).
The relationship between prevalence rates of unilateral PHI
and all PHI (uni- and bilateral) was calculated for NICU infants
and infants in the general neonatal population. Among the gen-
eral infant population, 34% [25, 42%] of infants with PHI have a
Table 3. Overview of the 35 studies in this review.
Author (ref) Year data Geography Scale
General population of infants
Adachi et al. (2010) 1999–2008 Japan (Saitama) Region
Adelola et al. (2010) 2000–2007 Ireland (Galway) Region
Antoni et al. (2016) 2005–2010 France (^Ile de France) Region
Augustine et al. (2014) 2010 India (Vellore) Hospital
Bailey et al. (2002) 2000–2001 Australia (Perth) City, 5 hospitals
Berninger and Westling (2011) 1999–2004 Sweden (Stockholm) City, 2 hospitals
Bevilacqua et al. (2010) 2005–2007 Brazil (Bauru) Hospital
Calcutt et al. (2016) 2009–2011 Australia (Queensland) Region
Dalzell et al. (2000) 1995–1996 USA (New York state) Region
De Capua et al. (2007) 1998–2006 Italy (Siena) Region
Farhat et al. (2015) 2008–2010 Iran (Mashad) City, 3 hospitals
Hsu, Lee, and Huang (2013) 2009–2010 Taiwan (Taipei) Hospital
Kennedy et al. (1998) 1993–1996 UK (South-West England) 4 cities
Magnani et al. (2015) 2010–2013 Italy (Parma) Hospital
Mason and Herrmann (1998) 1992–1997 USA (Honolulu, Hawaii) Hospital
Mehl and Thomson (2002) 1992–1999 USA (Colorado) State
Neumann et al. (2006) 2005 Germany (Hessen) Region
Ng et al. (2004) 1999 China (Hong Kong) Hospital
Olusanya and Somefun (2009) 2005–2008 Nigeria (Lagos) City, several clinics
Pastorino et al. (2007) 1997–2001 Italy (Milan) Hospital
Qi et al. (2013) 2007–2009 China (Beijing) Hospital
Sun et al. (2009) 2002–2007 China (Shanghai) Region
Swanepoel et al. (2007) 2001–2005 South Africa (Gauteng) Hospital
Uus and Bamford (2006) 2003–2004 UK (England) Country
Watkin and Baldwin (1999) 1992–1997 UK (London) Hospital
Wenjin et al. (2018) 2012–2014 China (Guangxi) Hospital
Wroblevska et al. (2017) 2013 Poland (Poznan) Hospital
WB only
Iwasaki et al. (2003) 2000–2001 Japan (Hamamatsu) City, 2 hospitals
Van der Ploeg et al. (2012) 2002–2009 Netherlands Country
Van Kerschaver et al. (2013) 2003–2004 Belgium (Flanders) Country
NICU only
Galambos, Wilson, and Silva (1994) 1977–1991 USA (San Diego, CA) City, 3 hospitals
Tajik and Ahmadpour-Kacho (2016) 2011–2015 Iran (Babol) City, 2 hospitals
Van Dommelen et al. (2010) 2002–2005 Netherlands Country
Van Straaten et al. (2007) 1998–2000 Netherlands Country
Watson, McClelland, and Adams (1996) 1982–1987 N-Ireland (Belfast) Hospital
Figure 2. The number of studies per score for each quality criterion.
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unilateral loss. Among NICU infants, 22% [12, 30%] of infants
with PHI have a unilateral loss.
The first sensitivity analysis showed that, when only studies
with a high-quality score (>75%) were included, the overall
prevalence rate was 1.75 per 1000 [1.16, 2.37]. The second sensi-
tivity analysis concerned the threshold of PHI. When a stricter
criterion was applied for the threshold (35 dB HL), the overall
prevalence rate was 2.14 per 1000 [1.47, 2.88]. Both sensitivity
analyses found overall prevalence rates that did not differ signifi-
cantly from the overall prevalence rate in the general population.
We included all selected studies regardless of quality score and
choice of threshold in the meta-analyses.
Table 4. Geographical areas from selected articles, reported prevalence rates of PHI (bi- and unilateral) and PHI bi (bilateral only), for general neonatal, WB and
NICU populations, including HI threshold, quality score and LTFU.
Country (region, city) N Pop Threshold P per 1000 P bi per 1000 Quality >75% LTFU <30%
General population of infants
Ireland (Galway) (Adelola et al. 2010) 25.742 40 dB 1.2 0.7 þ þ
Sweden (Stockholm) (Berninger and Westling 2011) 31.092 40 dB 1.7  
UK (South-West England) (Kennedy et al. 1998) 21.279 40 dB 1.3 þ 
UK (England) (Uus and Bamford 2006) 169.487 40 dB 1.0  
UK (London) (Watkin and Baldwin 1999) 25.199 40 dB 1.7 1.4 þ þ
Germany (Hessen) (Neumann et al. 2006) 17.439 40 dB 2.1 1.7 þ þ
France (Ile de France) (Antoni et al. 2016) 26.780 35 dB 0.6 þ þ
Italy (Siena) (De Capua et al. 2007) 19.700 30 dB 1.8 1.2 þ þ
Italy (Parma) (Magnani et al. 2015) 11.592 40 dB 3.3 2.2  þ
Italy (Milan) (Pastorino et al. 2007) 19.777 40 dB 3.2 1.7 þ þ
Poland (Poznan) (Wroblewska-Seniuk et al. 2017) 6.827 40 dB 3.1 2.5  þ
Japan (Saitama) (Adachi et al. 2010) 101.912 35 dB 3.1 1.6 þ 
China (Hong Kong) (Ng et al. 2004) 1.064 40 dB 5.6 2.8  
China (Beijing) (Qi et al. 2013) 10.983 30 dB 3.2 1.1  
China (Guangxi) (Wenjin et al. 2018) 19.098 30 dB 2.3  
China (Shanghai) (Sun et al. 2009) 560.432 40 dB 1.0 1.2(1) þ 
Taiwan (Taipei) (Hsu, Lee, and Huang 2013) 3.361 35 dB 1.5 0.6  þ
Iran (Mashad) (Farhat et al. 2015) 8.987 25 dB 3.5  þ
India (Vellore) (Augustine et al. 2014) 9.448 35 dB 4.1 3.2  
USA (New York state) (Dalzell et al. 2000) 43.311 20 dB 2.0 1.1  
USA (Colorado) (Mehl and Thomson 2002) 55.324 40 dB 1.5 1.1(2) þ þ
USA, Hawaii (Honolulu) (Mason and Herrmann 1998) 10.372 35 dB 1.4  þ
Brazil (Bauru) (Bevilacqua et al. 2010) 11.466 40 dB 1.0 0.8  þ
Nigeria (Lagos) (Olusanya and Somefun 2009) 11.897 40 dB 6.0 4.8  
South Africa (Gauteng) (Swanepoel et al. 2007) 6.241 35 dB 1.0 0.6  
Australia (Perth) (Bailey et al. 2002) 12.708 35 dB 0.7  þ
Australia (Queensland) (Calcutt et al. 2016) 175.911 40 dB 0.7(3) þ þ
WB
Netherlands (Van Der Ploeg et al. 2012) 547.061 40 dB 1.3 0.8 þ þ
Belgium (Flanders) (Van Kerschaver et al. 2013) 103.835 35 dB 1.5 0.9 þ þ
Japan (Hamamatsu) (Iwasaki et al. 2003) 4.085 40 dB 3.7 2.0  þ
China (Guangxi) (Wenjin et al. 2018) 12.134 30 dB 1.98  
Iran (Mashad) (Farhat et al. 2015) 8.724 25 dB 3.0  þ
USA, Hawaii (Honolulu) (Mason and Herrmann 1998) 8.971 35 dB 0.9  
NIC
Netherlands (Van Dommelen et al. 2010) 10.830 35 dB 18 15  
Netherlands (Van Straaten et al. 2007) 2.484 35 dB 24 18  þ
N-Ireland (Belfast) (Watson, McClelland, and Adams 1996) 417 40 dB 21 17  þ
China (Guangxi) (Wenjin et al. 2018) 6.964 30 dB 2.7 2.0  
Iran (Mashad) (Farhat et al. 2015) 263 25 dB 19  þ
Iran (Babol) (Tajik and Ahmadpour-Kacho 2016) 3.362 20 dB 11 10  
USA, Hawaii (Honolulu) (Mason and Herrmann 1998) 1.401 35 dB 5  þ
USA (San Diego CA) (Galambos, Wilson, and Silva 1994) 5.901 35 dB 47 33  
Pop: population; P: prevalence rate; (1) threshold of 25 dB, (2) 35 dB, (3) only sensorineural PHI; LTFU: lost to follow-up.; þ: meets criteria; : does not meet criteria
Table 5. Overall prevalence rates in a Bayesian random-effects model.
Overall prevalence rate (per 1000) Credible interval (per 1000) Number of studies
General population PHI 2.21 1.71, 2.8 20
General population bilateral PHI 1.33 1.01, 1.63 23
General population unilateral PHI 0.78 0.51, 1.07 16
Well babies 1.93 1.06, 2.98 5
NICU infants 15.77 4.65, 29.52 7
General population PHI, high quality studies 1.75 1.16, 2.37 8
General population PHI, threshold 35 dB HL 2.14 1.47, 2.88 15
Ratio Credible interval Number of studies
Ratio uni/uniþ bi in general population 0.34 0.25, 0.42 16
Ratio uni/uniþ bi in NICU infants 0.22 0.12, 0.3 6
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Analysis of variations in prevalence rates
For the analysis between geographical areas and prevalence rates
of PHI, geographical areas were categorised into five continents.
Despite the appearance of prevalence rates varying by geograph-
ical area, no statistically significant differences were found
(Figure 4, See Supplementary Appendix 2 material) Prevalence
rates seemed to be higher in Asia compared to Europe, but the
difference was not statistically significant (p¼ 0.06). The relation-
ship between PHI prevalence rate and GNI per capita was not
statistically significant (p¼ 0.29) according to the Bayesian logis-
tic regression analysis. No significant trend was observed
between prevalence rate and the year in which the data had been
collected (p¼ 0.12). Additionally, no significant association was
observed between prevalence rate and the percentage of infants
LTFU during the screening and diagnostic process (p¼ 0.16).
Larger percentages LTFU were generally associated with lower
GNI per capita, but this association did not reach statistical sig-
nificance (p¼ 0.07).
Discussion
In this systematic review and meta-analysis, the prevalence of
PHI in neonatal populations worldwide was investigated, as well
as possible associations between prevalence and its determinants.
The overall prevalence rate of PHI of 40 dB HL or worse in one
or both ears, was 2.21 per 1000. As expected, the prevalence rate
of PHI in NICU infants was much higher when compared to
both WB and all infants, confirming earlier reports (Garinis
et al. 2018; Wang et al. 2017).
Interestingly, a PHI is more likely to be bilateral in NICU
infants compared to the general infant population. PHI in NICU
infants is more likely to be acquired as the consequence of,
among others, infections, hyperbilirubinemia, hypoxia or
ototoxic medication. These risk factors for PHI would seem to
have an effect on both ears, while other causes may affect one or
both ears (Garinis et al. 2018; Wang et al. 2017; Hille
et al. 2007).
The highest prevalence rates were reported by studies per-
formed in Nigeria (Olusanya and Somefun 2009), India
(Augustine et al. 2014), China (Hong-Kong) (Ng et al. 2004) and
Iran (Farhat et al. 2015), but they concerned rather small popula-
tions. The lowest prevalence rates were found in Ireland (Adelola
et al. 2010), South Africa (Swanepoel et al. 2007), Brazil
(Bevilacqua et al. 2010) and China (Shanghai) (Sun et al. 2009).
Prevalence rates were higher in studies from Asia than
Europe, however, this difference was not statistically significant.
Countries with lower GNI per capita appeared to have higher
but widely distributed, prevalence rates. A statistical association
between prevalence and GNI was not found. Higher prevalence
rates in developing countries and higher prevalence rates in Asia
compared to Europe, were found by Stevens and Mathers in
their WHO studies (Mathers, Smith, and Concha 2003; Stevens
et al. 2013). These studies, however, concern older children,
include conductive HI and apply various thresholds. The current
study concerns neonates, PHI and strictly defined thresholds.
The current study did not demonstrate a statistically significant
association between the prevalence of PHI in the neonatal period
and geographical region or low- and high-income countries, but
such an association may still exist.
Unfortunately, both the current study and those by Stevens
and Mathers contain a sparsity of data from low-income coun-
tries (Mathers, Smith, and Concha 2003; Stevens et al. 2013).
Although this review includes studies from all over the world,
the majority of the studies report on results of NHS programmes
in high-income countries or large cities. Far less information is
available from Africa and South America. The results of this
review inevitably reflect a great extent the situation in high-
Figure 3. Bayesian random-effects model, PHI prevalence rates (per 1000) of the general neonatal population sorted by GNI per capita. (Tau: 0.51 95% CI [0.34, 0.73]).
(Event: number of infants with PHI; Weighted prevalence for each study; GNI: gross national income). Please note that the prevalence rates in this figure are based
on the fitted random-effects model and thus differ from the prevalence rates in Table 4. This discrepancy is due to the so-called shrinkage estimates that occur in ran-
dom-effects models.
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income countries, which possibly causes an under- or overesti-
mation of the overall prevalence rate. It is obvious that there is a
strong need for more prevalence studies from low-income coun-
tries and regions.
The prevalence rate of PHI, as reported in a study, should be
considered with caution. The reported prevalence rate in an
approximation of the “real” prevalence rate and is not only
determined by medical factors, but also by study factors. Medical
factors determine the “real” prevalence, which is the factual (but
unknown) number of infants affected in a population. A study
uses methods (study factors) to reveal the “real” prevalence.
Unfortunately, these methods may influence the outcome to an
unknown extent.
Direct medical factors include genetic disorders, antenatal or
postnatal infections, hyperbilirubinemia, hypoxia, medication
(aminoglycosides, diuretics). Indirect medical factors include the
availability and quality of health care provisions such as birth
clinics, NICU and vaccination programmes, but also consanguin-
ity and mortality rates. These factors are highly dependent on
social, economic and cultural circumstances, and therefore, likely
to vary considerably across countries. Congenital CMV is one of
the most important non-genetic causes of PHI in neonates
(Grosse, Ross, and Dollard 2008). It was found to be more
prevalent in Nigeria, China, India and the Middle East (Zuhair
et al. 2019). The incidence of infectious diseases and presence of
vaccination programmes are likely to be associated with the eco-
nomic situation of a country (Stevens et al. 2013), in contrast to
global distribution of genes causing HI, and the prevalence of
consanguineous marriages (Mathers, Smith, and Concha 2003;
Stevens et al. 2013; Freeland, Jones, and Mohammed 2010).
Consanguinity is especially common in North-Africa, the Middle
East, South-West Asia and India (Black 2018). Neonatal PHI is
assumed to be hereditary in more than 50% of cases, the major-
ity being autosomal recessive (Grundfast 2002; Smith and
Taggart 2004; Denoyelle et al. 1997; Zelante et al. 1997). As
aetiological data on neonatal PHI mainly originate from devel-
oped countries, we cannot be certain whether this percentage
also applies to the rest of the world. Study of the distribution of
the numerous genes associated with HI across the world is com-
plex, but more information is gradually becoming available
(Chan and Chang 2014).
This systematic review targets “real” prevalence rates and how
they depend on medical, economic and cultural circumstances.
Nevertheless, the differences in study design and screening pro-
cedures between articles must be considered, as these factors
influence the reported prevalence rates.
Study factors are the choice of the population studied, its size
and composition, the definition of PHI, including the threshold,
characteristics and quality of the audiometric testing and num-
bers of infants LTFU. The selected population determines to a
large extent the reliability and relevance of a reported prevalence
rate. The definition of PHI, the type and threshold used, has an
effect on the reported prevalence rate. A poorly performed test
will lead to more false “refers”, and thus more re-testing, which
is likely to increase the number of infants LTFU. A high percent-
age LTFU will result in an underestimated prevalence rate
because the denominator (the population) is usually defined as
the number of neonates entering the screening programme or
study group. The high percentage of infants LTFU may contrib-
ute to the reported low prevalence rate in the study by Sun in
Shanghai (Sun et al. 2009). The number of infants LTFU may be
especially high in developing countries, as the socio-economic
circumstances too often impede the functioning and use of
medical facilities. This implies that the “real” PHI prevalence
rates in developing countries could be even higher than the
reported ones. Although the assumption that LTFU may be asso-
ciated with GNI, was not confirmed by the statistical analysis
(p¼ 0.07), inclusion of more data from high-quality studies
could possibly make a difference. The prevalence rate calculated
for studies with a high-quality score was 1.75 per 1000, and the
prevalence rate for all included studies was 2.21 per 1000.
However, this result could have been biased by regional factors,
as most high-quality studies were performed in Western Europe.
Proposal reporting prevalence
Several studies reported on prevalence rates but did not describe
their results in a way that was useful for this study. There is
clearly no uniform methodology for defining, calculating or
reporting data on prevalence rates of HI. Therefore, it is pro-
posed that future studies reporting on prevalence rates define the
studied type(s) of HI in terms of sensorineural, permanent con-
ductive, transient conductive and mixed HI, with a defined cut-
off value (preferably 40 dB HL in neonates) for prevalence rate
calculation; indicate if HI is bilateral, unilateral or both bi- and
unilateral; use the most recent WHO (2018) classification to
report on the degree of HI; state the age at which the diagnosis
is definitive, the audiometric tests used for screening and diag-
nostics, the study group size, composition, proportion NICU/
WB, and number of infants LTFU.
Conclusion
Worldwide prevalence rates of HI in children of various age
groups are becoming increasingly available, partially due to the
ongoing implementation of universal NHS programmes. Much
of the existing information concerns older children, and reported
prevalence rates in neonates originate mainly from high-income
countries. Our systematic review shows that approximately 2 per
1000 neonates worldwide are identified with neonatal PHI, of
which approximately two-thirds are bilateral. Although no statis-
tical significant correlations were found with demographic or
study factors, prevalence rates in neonates tend to be higher in
countries with lower incomes, and higher in Asia than in
Europe. A marked lack of uniformity exists in studies, especially
with regard to the definition of HI.
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